Condition
Severe infections caused by Gram-negative bacteria
Total Trials
1
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Bal2420 Or Placebo
Research Leaders
8 sponsors active, led by Basilea Pharmaceutica International AG Allschwil
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 1 (1)
Trial Status
Recruiting1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Bal2420 Or Placebo1
Active Sponsors
- Basilea Pharmaceutica International AG Allschwil1
- Basilea Pharmaceutica1
- Wellcome Trust 325026/Z/25/Z1
- Health Emergency Preparedness and Response Authority1
- Italian Ministry of Economy and Finance1
Top Investigators
Basilea Pharmaceutica International Ltd, Allschwil
Related Conditions
- Healthy1